A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03299829

Enrollment

Registered

2017-10-03

Start date

2018-01-10

Completion date

2019-12-30

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trientine Treatment for Wilson's Disease

Keywords

trientine, Wilson's disease

Brief summary

This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients

Detailed description

In this retrospective study, the investigators will collect and analyze data from reviewing medical history files of larger and long-term follow-up cohorts with Wilson's disease in Taiwan to assess the efficacy and safety of Trientine in Taiwanese Wilson's Disease patients.

Interventions

DRUGTrientine

Trientine is a chelating agent for removing the copper from the body

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

3 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Wilson's disease. * Male or female patients, aged 3 years to 75 years

Exclusion criteria

* Patients with comorbidity which is not related to Wilson's disease.

Design outcomes

Primary

Measure	Time frame	Description
The improvement in liver function	Up to 1 year	To measure the AST (aspartate aminotransferase), ALT (alanine transaminase), GGT (gamma-glutamyl transpeptidase), Albumin, and Bilirubin level, and compare to the baseline

Secondary

Measure	Time frame	Description
The improvement in urine copper excretion	Up to 1 year	To measure 24-hour urine copper levels during the study period

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026